Company intelligence / Profile preview
Scintomics GmbH
Gräfelfing, Munich, Fuerstenfeldbruck, Bavaria/Bayern, Germanyscintomics.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Scintomics has developed a portfolio of unique radiopharmaceuticals focused on cancer diagnostics and therapeutics. Its radiohybrid PSMA-targeted PET imaging agent was approved by the FDA as POSLUMA® through Blue Earth Diagnostics. The company’s pipeline includes agents targeting PSMA and CXCR4 receptors for both imaging and therapy. Multiple programs are in clinical development or partnered with major pharma companies for commercialization.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsSmall molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Blue Earth Diagnostics / Bracco Imaging S.p.A.: Exclusive worldwide rights to therapeutic applications of radiohybrid PSMA technology in prostate cancer; commercialized POSLUMA®.POINT Biopharma Inc.: License agreement covering next-generation PSMA radioligands.PentixaPharm joint venture with 1717 Life Science Ventures to develop the PentixaFor/PentixaTher program targeting CXCR4.
Beyond the preview
Go deeper on Scintomics GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scintomics GmbH.